163 related articles for article (PubMed ID: 32175313)
1. Development of a CDK10/CycM
Robert T; Johnson JL; Guichaoua R; Yaron TM; Bach S; Cantley LC; Colas P
Front Chem; 2020; 8():147. PubMed ID: 32175313
[TBL] [Abstract][Full Text] [Related]
2. STAR syndrome-associated CDK10/Cyclin M regulates actin network architecture and ciliogenesis.
Guen VJ; Gamble C; Perez DE; Bourassa S; Zappel H; Gärtner J; Lees JA; Colas P
Cell Cycle; 2016; 15(5):678-88. PubMed ID: 27104747
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of CDK10 and cyclin M truncated variants causing severe developmental disorders.
Robert T; Dock-Bregeon AC; Colas P
Mol Genet Genomic Med; 2021 Oct; 9(10):e1782. PubMed ID: 34369103
[TBL] [Abstract][Full Text] [Related]
4. The awakening of the CDK10/Cyclin M protein kinase.
Guen VJ; Gamble C; Lees JA; Colas P
Oncotarget; 2017 Jul; 8(30):50174-50186. PubMed ID: 28178678
[TBL] [Abstract][Full Text] [Related]
5. CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Bazzi ZA; Tai IT
Front Oncol; 2021; 11():655479. PubMed ID: 34277407
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of the human Cdk10/Cyclin Q complex.
Düster R; Ji Y; Pan KT; Urlaub H; Geyer M
Open Biol; 2022 Mar; 12(3):210381. PubMed ID: 35291876
[TBL] [Abstract][Full Text] [Related]
7. A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
Guen VJ; Edvardson S; Fraenkel ND; Fattal-Valevski A; Jalas C; Anteby I; Shaag A; Dor T; Gillis D; Kerem E; Lees JA; Colas P; Elpeleg O
Am J Med Genet A; 2018 Jan; 176(1):92-98. PubMed ID: 29130579
[TBL] [Abstract][Full Text] [Related]
8. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
Guen VJ; Gamble C; Flajolet M; Unger S; Thollet A; Ferandin Y; Superti-Furga A; Cohen PA; Meijer L; Colas P
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19525-30. PubMed ID: 24218572
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M; Zhang L; Hei R; Li X; Cai H; Wu X; Zheng Q; Cai C
Am J Cancer Res; 2021; 11(5):1913-1935. PubMed ID: 34094661
[TBL] [Abstract][Full Text] [Related]
14. Identification of murine cdk10: association with Ets2 transcription factor and effects on the cell cycle.
Bagella L; Giacinti C; Simone C; Giordano A
J Cell Biochem; 2006 Oct; 99(3):978-85. PubMed ID: 16741970
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cyclin-dependent kinase 10 (CDK10) on the tamoxifen sensitivity of keloid samples.
Liu Y; Xiao Z; Yang D; Ren L; Liu G; Yang L
Molecules; 2012 Feb; 17(2):1307-18. PubMed ID: 22298115
[TBL] [Abstract][Full Text] [Related]
16. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
17. In a nongenomic action, steroid hormone 20-hydroxyecdysone induces phosphorylation of cyclin-dependent kinase 10 to promote gene transcription.
Liu W; Cai MJ; Wang JX; Zhao XF
Endocrinology; 2014 May; 155(5):1738-50. PubMed ID: 24517229
[TBL] [Abstract][Full Text] [Related]
18. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
20. CDK10 Mutations in Humans and Mice Cause Severe Growth Retardation, Spine Malformations, and Developmental Delays.
Windpassinger C; Piard J; Bonnard C; Alfadhel M; Lim S; Bisteau X; Blouin S; Ali NB; Ng AYJ; Lu H; Tohari S; Talib SZA; van Hul N; Caldez MJ; Van Maldergem L; Yigit G; Kayserili H; Youssef SA; Coppola V; de Bruin A; Tessarollo L; Choi H; Rupp V; Roetzer K; Roschger P; Klaushofer K; Altmüller J; Roy S; Venkatesh B; Ganger R; Grill F; Ben Chehida F; Wollnik B; Altunoglu U; Al Kaissi A; Reversade B; Kaldis P
Am J Hum Genet; 2017 Sep; 101(3):391-403. PubMed ID: 28886341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
